Development of Magnetic Resonance Imaging - Positron Emission Tomography (MRI-PET) Image Biomarkers for Brain Tumour Grading, Delineation and Measuring Early Treatment Response

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12609000877280

Acronym

FDOPA PET - MRI

Enrollment

100

Registered

2009-10-07

Start date

2009-07-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Eligible patients - brain tumour Aim - to develop new, more sensitive Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) measures for detecting early treatment response Treated as per standard practice with the addition of 3 3,4-dihydroxy-6-fluoro-phenylalanine (FDOPA) PET scans.

Interventions

3,4-dihydroxy-6-fluoro-phenylalanine(FDOPA) PET - MRI Brain tumour patients will be observed from diagnosis until 12 months post treatment

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

Brain tumour

Exclusion criteria

Inability to have standard clinical practice MRI or clinical trial FDOPA PET

Outcome results